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Variant Creutzfeldt-Jakob disease strain is
identical in individuals of two PRNP codon 129
genotypes
Abigail B. Diack,1 Aileen Boyle,1 Christopher Plinston,1 Emma Hunt,1
Matthew T. Bishop,2,† Robert G. Will2,* and Jean C. Manson3,4,*
*These authors contributed equally to this work.
In 2004, a subclinical case of variant Creutzfeldt-Jakob disease in a PRNP 129 methionine/valine heterozygous individual infected
via blood transfusion was reported, and we established that the spleen from this individual was infectious. Since host genetics is an
important factor in strain modiﬁcation, the identiﬁcation of variant Creutzfeldt-Jakob disease infection in a PRNP 129 methionine/
valine heterozygous individual has raised the possibility that the properties of the variant Creutzfeldt-Jakob disease agent could
change after transmission to this different genetic background and concerns that this could lead to a more virulent strain of variant
Creutzfeldt-Jakob disease. The variant Creutzfeldt-Jakob disease strain has to date been characterized only in methionine homo-
zygous individuals, therefore to establish whether the strain characteristics of variant Creutzfeldt-Jakob disease had been modiﬁed
by the host genotype, spleen material with prion protein deposition from a PRNP 129 methionine/valine individual was inoculated
into a panel of wild-type mice. Three passages in mice were undertaken to allow stabilization of the strain characteristics following
its passage into mice. In each passage, a combination of clinical signs, neuropathology (transmissible spongiform encephalopathy
vacuolation and prion protein deposition) were analysed and biochemical analysis carried out. While some differences were
observed at primary and ﬁrst subpassage, following the second subpassage, strain characteristics in the methionine/valine individ-
ual were totally consistent with those of variant Creutzfeldt-Jakob disease transmitted to 129 methionine/valine individuals thus
demonstrated no alteration in strain properties were imposed by passage through the different host genotype. Thus we have
demonstrated variant Creutzfeldt-Jakob disease strain properties are not affected by transmission through an individual with the
PRNP methionine/valine codon 129 genotype and thus no alteration in virulence should be associated with the different host
genotype.
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Introduction
Variant Creutzfeldt-Jakob disease (vCJD) is an acquired
prion disease linked to the consumption of food products
contaminated with the bovine spongiform encephalopathy
(BSE) agent (Bruce et al., 1997; Hill et al., 1997) and was
ﬁrst reported in the UK in 1996. A peak in deaths was
recorded in 2000 and it has since declined with a total of
178 deaths between 1995 and 2018 in the UK (Will et al.,
1996; National CJD Research and Surveillance Unit, 2019).
Until 2016, all deﬁnite and probable cases of vCJD with
genotype data had occurred in the 129 methionine homo-
zygous (MM) genotype suggesting other genotypes may be
more resistant to vCJD. In 2016 the ﬁrst case of clinical
vCJD in a 129 methionine/valine heterozygous (MV) indi-
vidual was reported demonstrating that individuals with
other genotypes were susceptible to vCJD and raising the
possibility of a second wave of vCJD in individuals of this
genotype (Mok et al., 2017). Transmission studies in trans-
genic mice expressing human prion protein (PrP, encoded
by PRNP) had predicted that all three genotypes were sus-
ceptible to vCJD albeit with differences in susceptibility and
incubation period. The 129MV and 129VV genotypes were
predicted to have longer incubation periods than in the
129MM individuals and indeed 129MV and 129 valine
homozygous (VV) individuals may not develop clinical
signs of disease (Bishop et al., 2006). However, since
vCJD infection can reside in peripheral tissues there is po-
tential for onward transmission of infection from individ-
uals of all three genotypes (Bruce et al., 2001; Ritchie et al.,
2009).
Human to human transmission of vCJD has already been
demonstrated and while the majority of vCJD cases are
primary cases presumed to be acquired from BSE, three
clinical cases of vCJD have been identiﬁed in 129MM in-
dividuals who had received non-leucoreduced red blood cell
concentrates from asymptomatic UK donors (Llewelyn
et al., 2004; Hewitt et al., 2006; Wroe et al., 2006).
Evidence of misfolded PrP in peripheral tissues has been
identiﬁed in two other individuals linked to blood and
blood products, both of whom were of the 129MV geno-
type and remained asymptomatic until death from non-
vCJD related causes (Peden et al., 2004, 2010). Studies
on one of these individuals who had received a red blood
cell transfusion from a 129MM donor showed no evidence
of abnormal PrP in the brain but deposition in the spleen
and a cervical lymph node was observed (Peden et al.,
2004) and using protein misfolding cyclic ampliﬁcation
(PMCA), prion seeding potential was demonstrated in a
range of tissues (Bougard et al., 2016). Bioassay of the
spleen material from this individual also conﬁrmed the
presence of vCJD infectivity (Bishop et al., 2013). The
other 129MV individual was an adult haemophilic patient
who had received factor VIII concentrate prepared from
plasma pools known to include a donation from a vCJD
infected donor. In this case, spleen material tested positive
for the presence of PrPres by western blot analysis (Peden
et al., 2010).
Three retrospective studies of anonymized human appen-
dix samples have been carried out in the UK to ascertain
the prevalence of vCJD infection (Hilton et al., 2004;
Ironside et al., 2006; Gill et al., 2013; Public Health
England, 2016). The most recent study identiﬁed seven
positives out of 15 939 giving a prevalence of 1:2000 in-
dividuals carrying abnormal PrP (Public Health England,
2016). In these three retrospective studies, misfolded PrP
has been found in all three codon 129 genotypes.
The single nucleotide polymorphism at codon 129 of the
prion protein gene, PRNP, encoding either M or V, is
recognized as inﬂuencing host susceptibility and modifying
strain characteristics for human prion diseases such as
Creutzfeldt-Jakob disease, Kuru, Gerstmann-Stra¨ussler-
Scheinker syndrome and fatal familial insomnia (Lee
et al., 2001; Pocchiari et al., 2004; Kobayashi et al.,
2015). It was thus recognized that vCJD in different host
genotypes may display different strain characteristics.
We have reported previously the infectivity of spleen
tissue from an asymptomatic MV blood recipient (MVR)
and the spleen and brain tissue of the MM donor to that
individual (MMD) in RIII and transgenic mice (Bishop
et al., 2013). The transmission of MVR and spleen and
brain homogenate of the MMD into RIII mice also demon-
strated differences in incubation times and attack rates be-
tween the two inocula suggesting either differences in titre
of infectivity or different strain properties between MMD
and MVR (Bishop et al., 2013). It was therefore important
to determine the underlying reason for these differences
observed on the initial passage to mice, since strain differ-
ences could impact on the transmission potential of the
strains.
The MV case demonstrates that there is the risk of trans-
mission between asymptomatic individuals of the MV
genotype through blood transfusion or blood products.
With the possibility of strain modiﬁcation and adaptation
of the vCJD agent following transmission to a different
genotype, it is thus important to assess whether vCJD is
modiﬁed by the genetic background and whether there are
alterations in virulence or pathogenesis. To address this we
have carried out an extensive stain typing analysis on the
strain of agent found within the spleen of an asymptomatic
codon 129MV individual. We have established that the
characteristics of this strain are consistent with that of
vCJD from 129MM individuals. Thus we have demon-
strated that strain properties of vCJD are not altered by
the PRNP codon 129 genotype of an individual.
Materials and methods
Human tissue selection
Post-mortem tissue (brain and spleen 0.5–1.5 g) was collected
via the MRC Edinburgh Brain Bank, approved by a national
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ethics committee, in line with the Human Tissue (Scotland)
Act. Use of human tissue for post-mortem studies has been
reviewed and approved by the Sudden Death Brain Bank
ethics committee and the Academic and Clinical Central
Ofﬁce for Research and Development (ACCORD) Medical
Research Ethics Committee (AMREC). Clinical and demo-
graphic details are given in Table 1. Tissue samples were
homogenized at 10% (w/v) concentration in sterile physio-
logical saline and stored at 80C until use.
Mice and experimental design
A panel of three inbred wild-type mouse lines were used for
the transmission studies; RIII (also referred to as MR),
C57BL6 and VM. RIII and C57BL6 lines are of the Prnpa
genotype and VM are of the Prnpb genotype (Bruce et al.,
1991). This combination of mouse lines has been used for
the strain characterization of a number of human and
animal prion diseases and each line has a characteristic and
reproducible incubation period and pathology when inoculated
with vCJD.
To characterize the isolates of interest fully, a primary pass
(human to mouse) followed by two subpassages (mouse to
mouse) were carried out. Subpassage was undertaken from a
representative mouse from each mouse line that showed clin-
ical signs and had positive transmissible spongiform encephal-
opathy (TSE) pathology (TSE vacuolation or PrP deposition)
where possible. Brain material from this mouse was then
inoculated into the panel of wild-type mice; this process was
repeated for the second subpassage.
vCJD infection of mice
All animal studies were carried out in derogated CL3 facilities.
The mice were housed in individually ventilated cages under a
12-h light/dark cycle and given food and water ad libitum.
Cohorts of mice (n = 18–24, 6–8 weeks of age and sex
matched) were given prophylactic antibiotics (500ml strepto-
mycin and 500 IU penicillin) prior to inoculation with human
isolates. Mice were anaesthetized with isoﬂurane and inocu-
lated with 0.02ml of 10% homogenate via the intracerebral
(i.c) route and 0.1ml via the intraperitoneal route. The MM
recipient (MMR2008) CNS was inoculated by the intracerebral
route only because of limited tissue availability. For subpas-
sage, inocula were prepared with mouse brain tissue at 1% (w/v)
in physiological saline and mice inoculated with 20 ml via the
intracerebral route only. Tissue samples were irradiated prior
to second subpassage because of an animal house move.
Animal studies were approved by The Roslin Institute’s
Animal Welfare Ethical Review Board and were conducted
according to the regulations of the 1986 United Kingdom
Home Ofﬁce Animals (Scientiﬁc Procedures) Act.
Scoring of clinical TSE disease and
pathology
Mice were scored weekly for clinical signs from 100 (primary
pass) or 50 (subpassage) days post inoculation (dpi) by oper-
ators blind to isolate/cohort combination according to a pre-
viously established TSE clinical scoring system (Dickinson
et al., 1968). Mice were scored as unaffected, possibly affected
or deﬁnitely affected using standard criteria. Any unusual clin-
ical signs were noted and in older animals signs of ageing (loss
of body condition, reduced activity) were taken into account.
Mice were sacriﬁced after (i) two consecutive scores of deﬁn-
itely affected; (ii) after receiving scores of deﬁnitely affected in
2 of 3 weeks, or (iii) signiﬁcant deterioration of condition.
Mice with no signs of clinical disease were maintained until
700 dpi or until study termination.
Mice were sacriﬁced by cervical dislocation, the brains
removed and cut sagitally with one half frozen in liquid nitro-
gen for biochemistry and the remaining half ﬁxed in formal
saline for 48 h and decontaminated with formic acid when
required, prior to parafﬁn embedding. Coronal sections were
cut (6mm) and stained with haematoxylin and eosin and TSE-
speciﬁc vacuolation was quantitatively scored blind to isolate
and mouse line by a standard method in nine grey matter and
three white matter areas (Fraser and Dickinson, 1968). Mean
TSE vacuolation scores were plotted for groups of six mice or
more unless otherwise stated.
Prion protein detection by
immunohistochemistry
Coronal sections were stained using 6H4 antibody (1:500,
Prionics) (Korth et al., 1997) to detect PrP. Antigen retrieval
by autoclaving at 121C in citric acid buffer and a 5-min
formic acid (98%) treatment was used. Sections were then
blocked with normal rabbit serum prior to incubation with
Table 1 Demographic and clinical features of cases included in this study
Characteristics MVR blood recipient MMD blood donor to MV MMD2008 blood donor to MM MMR2008 blood
recipient
MRC reference number BBN001.34141 BBN_1037 BBN_1028 BBN_1052
Codon 129 genotype 129MV 129MM 129MM 129MM
Patient sex F F M M
Patient age at illness
onset, years
NA 28 23 68
Patient age at death, years 83 28 24 69
Disease duration, months NA 9 13 13
Case report and
further details
Peden et al., 2004;
Bishop et al., 2013
Bishop et al., 2013;
Urwin et al., 2016
Bishop et al., 2008;
Urwin et al., 2016
Bishop et al., 2008;
Urwin et al., 2016
F = female; M = male; MVR = asymptomatic MV blood recipient; MMD = the MM donor to the MVR; MMD2008 = an MM blood donor; MMR2008 = the MM blood recipient to MMD2008.
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the primary antibody. Antibody binding was detected with the
Vector ABC kit (Vector Laboratories) and visualized with 3,30
diaminobenzidine chromogen. All sections were counterstained
with haematoxylin.
Western blot analysis
Frozen brain samples were homogenized in NP40 buffer [20
mM Tris (pH 7.4), 0.5% v/v NP40 solution, 0.5% w/v sodium
deoxycholate] to give a 10% w/v suspension. The suspension
was further passaged through a 25G needle (twice) to break
up any remaining aggregates. The homogenate was combined
with 3% SDS and treated with 20 mg/ml proteinase K
(Novagen) for 1 h at 37C with shaking.
The prepared sample was suspended in equal volume of
Laemmli 2 sample buffer (Sigma-Aldrich) and treated at
100 for 10min. The products were then loaded onto a 4–
12% Bis/Tris gel (Thermo Fisher). After electrophoresis the
gel was blotted onto a PVDF membrane. Detection of PrP
was with primary antibody 6H4 (Prionics) (Korth et al.,
1997) at 1:5000 (for a minimum of 24 h at 4C with shaking)
and an anti-mouse infrared ﬂuorescence, IRDye secondary
antibody (LI-COR) at 1:5000. Images were captured with
the LI-COR Odyssey imaging system.
Data and statistical analysis
Animals in which clinical signs were present without patho-
logical (TSE vacuolation and/or PrP deposition) conﬁrmation
were removed from the analysis as these signs can also be due
to other conditions such as ageing. Animals in which no TSE
vacuolation score was available (due to tissue autolysis or
technical issues) were also discounted. Early intercurrent
deaths (under 200 dpi and 50 dpi for the primary and subpas-
sage, respectively) were excluded from the study. Raw data
and samples from previously published studies (Bishop et al.,
2008; Bishop et al., 2013) were reanalysed using the criteria
above to ensure a valid comparison between all datasets.
Statistical analyses for incubation periods were performed
using A Kruskal-Wallis test followed by Dunn’s multiple com-
parisons test using GraphPad Prism 7.0 for windows
(GraphPad Software, La Jolla California, USA).
Data availability
The data that support the ﬁndings of this study are available
from the corresponding author, upon reasonable request.
Results
In this study, we carried out a characterization study of the
MVR and MMD (CNS and spleen) at primary passage in
our strain typing panel of wild-type mice. This panel con-
sists of RIII and C57BL6 mice, both of the Prnpa genotype
and VM mice, Prnpb genotype. This combination of mouse
lines gives highly reproducible and characteristic incubation
periods (time between inoculation and death with clinical
signs), incubation period rankings (order in which mouse
lines succumb to disease) and neuropathology (TSE vacu-
olation and/or PrP deposition) when inoculated with the
BSE or vCJD prion strain. These results were compared
to a previously published transmission of brain homogenate
from a MM blood donor (MMD2008) and the associated
MM blood recipient (MMR2008) (Bishop et al., 2008). We
then carried out a second passage of MVR, MMD (CNS
and spleen), MMD2008 and MMR2008 and ﬁnally a third
passage of the MVR, MMD (CNS) and MMD2008 to
allow stabilization and full characterization of each strain.
Primary passage identified
differences between isolates
The inoculation of MVR (spleen) and MMD (spleen and
CNS) to the C57BL6 and VM mice resulted in positive
transmission with both clinical disease and/or TSE vacuol-
ation present in all isolate/mouse line combinations
(Table 2). This data were then analysed and compared
with the previously reported MVR and MMD RIII trans-
mission and the MMD2008 and MMR2008 data set.
On primary passage there were differences in attack rates
for clinical signs and TSE vacuolation between the isolates
with lower rates observed in both the MVR and MMD
(spleen) across all mouse lines when compared to the
MMD (CNS). In particular, there was only one VM
mouse scoring as clinically positive with no TSE
vacuolation (PrP deposition was present) from the MVR,
compared to 47% with TSE vacuolation from the MMD
(spleen) and 54% with TSE vacuolation in previously-re-
ported spleen transmissions from MM individuals (Ritchie
et al., 2009).
Incubation periods were calculated for each line and iso-
late combination for mice exhibiting both clinical signs and
TSE vacuolation and the incubation period ranking com-
pared between isolates and those of previous transmissions
(Fig. 1A). Incubation periods were increased for both MVR
and MMD (spleen) in the RIII, C57BL6 and VM mice when
compared to those of the MMD (CNS). The incubation
period ranking for the MMD (CNS) was of the order
RIII5C57BL65VM mice, similar to vCJD transmissions
reported previously. A full incubation period ranking was
unavailable for the MVR due to the absence of TSE vacu-
olation in the VM mice, this was also true of the MMD
(spleen) where no clinical signs were apparent in the
C57BL6 mice.
TSE vacuolation proﬁles for each line of mice were
generated where mouse numbers were sufﬁcient and then
compared. C57BL6 mice inoculated with MMD (CNS)
demonstrated similar targeting to that of a typical
129MM CNS transmission (Fig. 1B) with vacuolation tar-
geted to the medulla (G1) and hypothalamus (G4) regions.
MMD (CNS and spleen) showed similar targeting in VM
mice to typical 129MM transmissions with peaks in vacu-
olation intensity at the medulla (G1), thalamus (G5) and
septum (G7) regions although an additional peak was
observed in the MMD (CNS) transmission in the superior
colliculus (G3), hypothalamus (G4) and thalamus (G5)
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Figure 1 Comparison of incubation periods and TSE vacuolation profiles in wild-type mice challenged with brain and spleen
homogenates from four cases of vCJD. The four cases used to challenge wild-type mice were: an asymptomatic MV blood recipient (MVR),
the MM donor to that individual (MMD), an MM blood donor (MMD2008) and the associated MM blood recipient (MMR2008). (A) Incubation periods
in RIII, VM and C57BL6 mice. Incubation periods were calculated in mice showing clinical and pathological signs of TSE disease. (B) TSE
vacuolation profiles in C57BL6 mice (n5 6). (C) TSE vacuolation profiles in VM mice [n5 6 in MMD (CNS), MMR2008 and MMD2008, n = 4 in MMD
(spleen)]. (D) TSE vacuolation profiles in RIII mice (n5 6). All data shows mean  SEM. Brain region areas: G1–9, grey matter scoring areas; G1,
medulla; G2, cerebellum; G3, superior colliculus; G4, hypothalamus; G5, thalamus; G6, hippocampus; G7, septum; G8, retrosplenial and adjacent
motor cortex; G9, cingulate and adjacent motor cortex. W1–W3, white matter scoring regions: W1, cerebellar white matter; W2, mesencephalic
tegmentum; W3, cerebral peduncle. Dpi = days post inoculation.
Table 2 Incidence of clinical disease and TSE vacuolation wild-type mice challenged with vCJD cases
Isolate Mouse strain
RIII C57BL6 VM
Clinical signs TSE vacuolation Clinical signs TSE vacuolation Clinical signs TSE vacuolation
MVR (spleen) 11/20 (55%) 11/20 (55%) 2/22 (9%) 5/22 (23%) 1/20 (5%) 0/20 (0%)
MMD (CNS) 18/28 (64%) 21/28 (75%) 11/21 (52%) 18/21 (86%) 13/21 (62%) 18/21 (86%)
MMD (spleen) 5/20 (25%) 3/20 (15%) 0/21 (0%) 1/21 (5%) 4/19 (21%) 9/19 (47%)
MMD2008 (CNS) 21/23 (91%) 21/23 (91%) 14/23 (61%) 21/23 (91%) 20/24 (83%) 21/24 (88%)
MMR2008 (CNS) 18/22 (82%) 18/22 (82%) 0/14 (0%) 2/14 (14%) 15/22 (68%) 18/22 (82%)
MVR = asymptomatic MV blood recipient; MMD = the MM donor to the MVR; MMD2008 = an MM blood donor; MMR2008 = the MM blood recipient to MMD2008.
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(Fig. 1C). As reported previously, vacuolation proﬁles were
similar in RIII mice across MVR and MMD (spleen and
CNS) (Fig. 1D) with peaks in vacuolation intensity
observed at medulla (G1), hypothalamus (G4) and
septum (G7) regions (Bishop et al., 2013). The MMD
(CNS) transmission resulted in TSE vacuolation proﬁles in
RIII and C57BL6 mice that are similar to that of typical
129MM CNS transmissions. There was slight variation be-
tween the TSE vacuolation proﬁles of the MMD (CNS) and
MMD (spleen) in the VM mice which could indicate
changes in titre. MVR resembled that of typical vCJD in
129MM individuals in RIII mice and MMD showed typical
proﬁles in RIII and VM mice. No TSE vacuolation proﬁle
was possible in VM or C57BL6 mice from MVR because of
lack of TSE vacuolation.
Immunohistochemical analysis was carried out to assess
the amount and distribution of abnormal PrP deposition in
each mouse line inoculated with spleen homogenate from
the MVR and spleen and brain homogenate from the
MMD. Variability in the amount of abnormal PrP depos-
ition within experimental cohorts was apparent, but there
appeared to be no clear differences in PrP distribution be-
tween the isolates inoculated into the same mouse line. In
RIII mice, there was widespread PrP deposition of a granu-
lar nature in the hypothalamus and thalamus with a dis-
tinctive pattern of intense deposition of the CA2 region of
the hippocampus (Fig. 2A, D, G and J) typical of vCJD in
this mouse line. C57BL6 mice shared a similar deposition
pattern to that of RIII mice with the distinctive CA2 tar-
geting of the hippocampus (Fig. 2B, E, H and K). VM mice
exhibited widespread ﬁne punctate PrP deposition with
pericellular deposits particularly in the thalamus, hypothal-
amus, midbrain and hippocampus (Fig. 2C, F and I).
Occasional PrP plaques were observed in the corpus callo-
sum (Fig. 2L) and are a typical feature of vCJD in VM
mice.
When compared to previously-published 129MM vCJD
transmissions associated with blood transfusion (Bishop
et al., 2008), there were a number of differences apparent
in the MVR and MMD. These can be summarized as dif-
ferences in attack rates (clinical signs and TSE vacuolation),
increases in incubation periods and changes in TSE vacu-
olation proﬁles. The differences in attack rates between
spleen and CNS transmissions is thought to be as a result
of differences in titre, with peripheral organs such as the
spleen having lower titres. However, the differences be-
tween the MVR and MMD spleen transmissions particularly
in the VM mice could also be due to the modiﬁcation of
strain characteristics due to different host PRNP codon 129
genotype between MMD and MVR
Mouse subpassage of the MV and MM
isolates defined strain characteristics
Inconsistences are not unusual in primary passage to mice
due to crossing the species barrier and further passage is
required to establish if such differences truly represent
strain differences. Because of the variation observed upon
primary passage of the MVR and MMD isolates, mouse-to-
mouse subpassages of the MVR and MMD (CNS and
spleen) were undertaken in order to fully characterize the
prion strain of the isolates. In addition, we undertook sub-
passage of the MMD2008 and associated MMR2008 and the
ﬁve isolates were then compared.
Subpassage from Prnpa mice
A RIII or C57BL6 mouse which exhibited clinical signs and
had positive TSE pathology was inoculated into the panel
of wild-type mice and the strain characteristics analysed as
above. Subpassage of the MVR and MMD (CNS and
spleen) from both RIII and C57BL6 mice resulted in
100% susceptibility in both clinical signs and TSE vacu-
olation. Incubation period rankings were of the order
RIII5C57BL65VM (identical those of the MMD2008 and
MMR2008; however, there was a signiﬁcant decrease in in-
cubation time of the VM mice from the C57BL6 passage of
the MMD (CNS) compared to MVR (P5 0.001) and
MMD2008 (P50.01) (Fig. 3).
TSE vacuolation proﬁles were consistent between experi-
mental cohorts from the ﬁve isolates with vacuolation par-
ticularly noted in the hypothalamus (G4) and septum (G7)
of RIII and C57BL6 mice (Fig. 4A, B, G and H). There was
minor variation apparent in the C57BL6 to C57BL6 pas-
sage from the MVR where a peak in vacuolation intensity
could be observed in the thalamus (G5) (Fig. 4H, indicated
by an arrow). In VM mice, peaks in vacuolation intensity
were in the medulla (G1), thalamus (G5) and septum (G7)
(Fig. 4C and I). However, the C57BL6 to VM passage from
the MMD (CNS) (Fig. 4I) had only two peaks in vacuol-
ation intensity in the medulla (G1) and thalamus (G5).
There is minor variation in the MVR when compared to
the MM transmissions which could indicate that the strain
has not yet stabilized, differences were also noted for the
MMD (CNS).
There was a widespread distribution of abnormal PrP
deposition throughout the brain in all isolate/mouse line
combinations predominantly of a diffuse nature (Fig. 5A,
E and I). This was observed to be more intense in the
thalamus, medulla and hippocampus where the CA2
region was targeted. PrP plaques were also present in all
mouse lines/isolate combinations and were most commonly
present in the cerebellum and corpus callosum but to a
lesser degree in the MVR subpassage.
Subpassage from Prnpb mice
A VM mouse from each isolate exhibiting both clinical
signs and TSE pathology was inoculated into the wild-
type panel of mice and the strain characteristics analysed.
Subpassage of MMD (CNS and spleen) from VM mice
gave between 87 and 100% attack rates (clinical signs
and TSE vacuolation) to each mouse line whereas the
subpassage from the MVR in VM mice exhibited lower
attack rates. These lower attack rates were particularly
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Figure 2 Abnormal PrP deposition in wild-type mice challenged with brain and spleen homogenates from two cases of vCJD.
The two cases comprised an asymptomatic MV blood recipient (MVR) and the MM donor to that individual (MMD CNS and spleen). (A) RIII,
(B) C57BL6, and (C) VM, mice challenged with MVR. (D) RIII, (E) C57BL6, and (F) VM, mice challenged with MMD (CNS). (G) RIII, (H) C57BL6,
and (I) VM, mice challenged with MMD (Spleen). (J) Abnormal PrP deposition in CA2 region of hippocampus from RIII mouse (inset region of A).
(K) Abnormal PrP deposition in CA2 region of hippocampus from C57BL6 mouse (inset region of E). (L) PrP plaque in the corpus callosum of a
VM mouse (inset region of F). Scale bars = 200 mm (A–I); 100 mm (J–L).
Figure 3 Incubation periods in wild-type (RIII, C57BL6 and VM) mice from the first and second mouse subpassage of brain and
spleen homogenates from four cases of vCJD. The four cases comprise: an asymptomatic MV blood recipient (MVR), the MM donor to that
individual (MMD), an MM blood donor (MMD2008) and the associated MM blood recipient (MMR2008). Incubation periods were calculated in mice
showing clinical and pathological signs of TSE disease. Black box indicates significant changes in incubation periods (P5 0.05). All data shows
mean  SEM. Dpi = days post inoculation.
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Figure 4 TSE vacuolation profiles in wild-type mice from the first and second mouse subpassage of brain and spleen hom-
ogenates from four cases of vCJD. The four cases comprise: an asymptomatic MV blood recipient (MVR), the MM donor to that individual
(MMD), an MM blood donor (MMD2008) and the associated MM blood recipient (MMR2008). (A–C) First mouse subpassage from RIII mice. (D–F)
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evident in the RIII line (18% clinical, 24% TSE vacuol-
ation positive) and VM line (33% clinical, 60% TSE vacu-
olation positive). Incubation period rankings were of the
order RIII5C57BL65VM from all isolates except the
MV recipient. The ranking from the MVR was of the
order RIII5VM5C57BL6 with a signiﬁcant increase in
incubation period in RIII mice when compared to MMD
(spleen) (P50.05) and MMR2008 (P5 0.001), in C57BL6
mice when compared to MMD (CNS and spleen),
MMR2008 and MMD2008 (P5 0.01) and in VM mice
when compared to MMD (CNS and spleen) (P5 0.01)
and MMR2008 (P5 0.01) (Fig. 3, indicated by black
box). All MM transmissions were consistent in their
attack rates and incubation period rankings regardless of
whether they originated from CNS or spleen tissue. In
contrast the MVR had lower attack rates and a different
incubation period ranking.
TSE vacuolation in RIII and C57BL6 mice from the
MMD (CNS and spleen) and C57BL6 mice from the
MVR was evident in the thalamus (G5) and septum (G7)
(Fig. 4M and N). The vacuolation proﬁle of the MVR in
the VM to C57BL6 passage showed a peak in vacuolation
in the hypothalamus (G4) which was different to the other
isolates that had a peak in the thalamus (G5) (Fig. 4N,
indicated by arrow). There were insufﬁcient mice from
the MVR subpassage to carry out a vacuolation proﬁle in
RIII and VM mice. The MMD (CNS) VM to VM subpas-
sage resulted in a similar proﬁle albeit at lower levels of
vacuolation to the MMD2008 and MMR2008. The MMD
(spleen) exhibited higher levels of vacuolation in the thal-
amus (G5) rather than hippocampus (G6) of VM mice as
was in the case in the other isolates (Fig. 4O, indicated by
arrow). The MM CNS transmissions all demonstrated con-
sistent TSE vacuolation proﬁles; however, the MMD
(spleen) showed minor variation in VM mice. The MVR
had differences in the VM to C57BL6 passage however
most striking was the lack of TSE vacuolation positive
RIII and VM mice.
Abnormal PrP accumulation was present in the mice with
diffuse and punctate accumulation observed throughout the
Figure 5 Abnormal PrP deposition in wild-type mice from the first and second mouse subpassage of brain and spleen hom-
ogenate from three cases of vCJD. The three cases comprise: an asymptomatic MV blood recipient (MVR), the MM donor to that individual
(MMD CNS) and an MM blood donor (MMD2008). (A) RIII mice from the first and (B) second subpassage of MVR. (C) VM mice from the first and
(D) second subpassage of MVR (E) RIII mice from the first and (F) second subpassage of MMD (CNS). (G) VM mice from the first and (H) second
subpassage of MMD (CNS). (I) RIII mice from the first and (J) second subpassage of MMD2008. (K) VM mice from the first and (L) second
subpassage of MMD20008 Scale bars = 200 mm (A–I).
Figure 4 Continued
Second mouse subpassage from RIII mice. (G–I) First mouse subpassage from C57BL6 mice. (J–L) Second mouse subpassage from C57BL6 mice.
(M–O) First mouse subpassage from VM mice. (P–R) Second mouse subpassage from VM mice. Arrows indicates changes from typical vacu-
olation profiles. All vacuolation profiles were calculated from n5 6, data show mean  SEM. Brain region areas: G1–9, grey matter scoring areas;
G1, medulla; G2, cerebellum; G3, superior colliculus; G4, hypothalamus; G5, thalamus; G6, hippocampus; G7, septum; G8, retrosplenial and
adjacent motor cortex; G9, cingulate and adjacent motor cortex. W1–W3, white matter scoring regions: W1, cerebellar white matter; W2,
mesencephalic tegmentum; W3, cerebral peduncle.
Identical vCJD strain in two PRNP 129 genotypes BRAIN 2019: 0; 1–13 | 9
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/advance-article-abstract/doi/10.1093/brain/aw
z076/5425354 by The U
niversity of Edinburgh user on 03 April 2019
brain particularly in the hippocampus and thalamus with
PrP plaques present on occasion in the corpus callosum and
cerebellum (Fig. 5C, G and K).
When compared to the typical MM subpassages,
MMD2008 and MMR2008, the MMD and MVR both demon-
strated differences in strain characteristics at the ﬁrst
mouse-to-mouse passage. Unexpectedly, we observed differ-
ences in the MMD (CNS) subpassage in incubation periods
and rankings and TSE vacuolation proﬁles whereas the
MMD (spleen) was more consistent with the typical MM
transmissions from CNS material. Of importance was that
differences were observed in the MVR subpassage in incu-
bation periods and rankings and TSE vacuolation proﬁles.
These changes in strain characteristics are unlikely to be
due to source material (spleen) as we did not observe simi-
lar changes in the MMD spleen and could be ascribed to
genotype of this individual.
Strain properties of the
asymptomatic MV individual are
identical to those of codon 129MM
individuals
As variation was still observed upon the ﬁrst mouse-to-
mouse subpassage, a second mouse-to-mouse subpassage
was performed from the MVR, MMD (CNS) and the
MMD2008. These isolates were chosen as a number of vari-
ations had been observed in the MVR and MMD (CNS)
subpassages, the MMD2008 was chosen as an example of
a typical vCJD subpassage The stabilization of a prion
strain can require multiple passages in the same host.
Once stabilized the incubation period and neuropatho-
logical characteristics will remain constant if they are con-
tinually propagated under constant conditions, i.e. PrP
genotype of the mice (Bruce, 2003).
Subpassage from Prnpa mice
In contrast to the ﬁrst mouse-to-mouse subpassage, the
second mouse-to-mouse passage of the MVR and MMD
(CNS) displayed 100% susceptibility in clinical signs
and TSE vacuolation across all experimental cohorts as
did the MMD2008. Incubation period rankings were in the
order RIII5C57BL5VM for isolates passaged through
RIII and C57BL6 mice as observed in the ﬁrst subpassage
of the MMD2008. The incubation period of VM mice of the
MMD (CNS) in the C57BL6 subpassage increased com-
pared to the ﬁrst subpassage thus giving a similar incuba-
tion period for the MMD2008 and MVR (Fig. 3). TSE
vacuolation proﬁles and PrP deposition patterns showed
no differences between the three isolates (Figs 4D–F, J–L
and 5B, F and J). Biochemical analysis of PrPres from the
RIII to RIII subpassage showed the same glycoproﬁle be-
tween MVR, MMD (CNS) and MMD2008 with a dominant
di-glycosylated fragment of 30 kDa and an unglycosylated
band of 20 kDa similar to that of the type 2B glycoproﬁle
observed from vCJD human brain tissue (Fig. 6A,
Supplementary 1). These results indicate that the same
strain of prion agent has been isolated from the MVR,
MMD (CNS) and MMD2008.
Subpassage from Prnpb mice
The second subpassage through VM mice of the MVR re-
sulted in a change of the ranking observed in the ﬁrst sub-
passage (RIII5VM5C57BL6); with all three isolates now
demonstrating the ranking VM5RIII5C57BL6 (Fig. 3).
TSE vacuolation proﬁles of the three isolates in the VM to
RIII and VM to C57BL6 subpassage followed the same
vacuolation trend in each mouse line and these were near
identical to the proﬁles resulting from the MMD2008 in the
ﬁrst subpassage (Fig. 4P and Q). PrP deposition patterns
were similar to that of RIII and C57BL6 mice with no dif-
ferences between the MVR and the two MM blood donors.
In the VM to VM subpassage, the MMD2008 exhibited a
greater intensity of TSE vacuolation overall; however, it
followed the same distribution pattern of vacuolation
with peaks in the medulla (G1) and hippocampus (G6).
As in the ﬁrst subpassage the MMD2008 exhibited greater
vacuolation intensity in the septum (G7), retrosplenial
cortex (G8) and cingulate and motor cortex (G9) than
the MMD (CNS) (Fig. 4R). There were no differences in
PrP deposition patterns (Fig. 5D, H and L). Upon VM to
VM subpassage there were no differences upon biochemical
analysis of the MVR, MMD (CNS) and MMD2008 isolates
with a dominant di-glycosylated fragment of 30 kDa,
mono-unglycosylated band of 27 kDa and an unglycosy-
lated fragment at 20 kDa (Fig. 6B, Supplementary 1).
Overall analysis of the strain properties of each isolate
indicates that two stable strains have emerged; one strain
Figure 6 Western blot analysis of brain extracts from the
second mouse subpassage of RIII (A) and VM (B) wild-type
mice challenged with three cases of vCJD. The three cases
comprised: an asymptomatic MV blood recipient (MVR), the MM
donor to that individual [MMD (CNS) and an MM blood donor
(MMD2008)]. A human vCJD standard positive control is shown for
reference with the typical abnormal prion protein (PrPres) type 2B.
All samples were treated with proteinase K (indicated by plus
symbol). The anti-prion protein detection antibody used was 6H4.
Molecular weight markers are shown in kDa. PK = Proteinase K.
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passaged through RIII and C57BL6 (Prnpa) mice and one
strain through VM (Prnpb) mice. These mouse-adapted
strains are consistent with those identiﬁed previously in
both 129MM vCJD and BSE (301C and 301V) transmis-
sion studies (Bruce et al., 2002; Ritchie et al., 2009). The
data presented here demonstrate that vCJD in an asymp-
tomatic MV individual is of an identical strain to that
identiﬁed in clinical vCJD individuals of the codon
129MM genotype. It also indicates human-to-human trans-
mission through different host genotypes has not caused
any strain adaptation and that the BSE/vCJD has remained
constant.
Discussion
This study provides the ﬁrst evidence that codon 129 geno-
type of the host does not inﬂuence the strain characteristics
of vCJD. In light of the identiﬁcation of a clinical MV case
of vCJD and abnormal PrP deposition in appendixes of all
codon 129 genotypes, this ﬁnding is important for public
health. Strain properties are often inﬂuenced by the PRNP
genetic background of the host and modiﬁcations in the
strain properties can result in different host ranges and
clinical outcomes; until now, it was unknown whether a
different genetic background could alter vCJD characteris-
tics. The characterization of the infectious agent from
spleen from this asymptomatic case of vCJD in a codon
129 heterozygous individual has provided answers to
these key questions.
Our study ﬁnds no evidence of a novel vCJD strain after
passage through an MV individual; however, this could be
because of the methionine-carrying prion proteins acting as
a dominant species. While other studies have demonstrated
that replication of the infectious agent is possible in all
three genotypes, the 129VV genotype was clearly less sus-
ceptible to disease (Bishop et al., 2006). Thus the presence
of methionine in the 129MV genotype may dominate any
replication process giving rise to strain characteristics iden-
tical to that in 129MM genotypes. At present, we cannot
be sure of the effect of valine homozygosity on strain char-
acteristics although mouse studies indicate there may be
potential for different strain characteristics to emerge
(Takeuchi et al., 2013; Fernandez-Borges et al., 2017).
Our initial study showed that the spleen of the MV re-
cipient was infectious (Bishop et al., 2013) but on this pri-
mary passage there were inconsistencies in strain
characteristics when compared with those of previously
characterised vCJD cases from MM individuals. The BSE/
vCJD strain has consistently produced unique characteris-
tics upon primary passage to mouse strain typing panels.
Most notably these include high attack rates, a character-
istic TSE vacuolation proﬁle in RIII mice and a consistent
incubation period ranking; RIII followed by C57BL6 100
days later than VM mice (Bruce et al., 1994, 1997; Ritchie
et al., 2009; Diack et al., 2012, 2017). The majority of
prion strains tend to show low attack rates with long
incubation periods upon primary passage. Further mouse
subpassages generally show a shortening in incubation per-
iods and 100% susceptibility in terms of clinical and
pathological signs of disease indicative of the removal of
the species barrier. These properties then remain consistent
throughout further subpassages (Bruce, 2003). As the stu-
dies in the MV recipient demonstrated inconsistences at
primary passage, a full strain characterization study was
required. However, the strain characteristics stabilized
and were identical to that of previous vCJD and BSE trans-
missions with the second mouse subpassage resulting in
either a 301C or 301V type TSE strain as determined by
mouse line (Bruce et al., 2002; Ritchie et al., 2009).
The inconsistences noted at primary passage in attack
rate and lack of TSE vacuolation, could have been a con-
sequence of the interaction between human and mouse gen-
etic backgrounds i.e. PRNP codon 129 genotype and Prnpa
or Prnpb or could be due to a lower titre of infectivity in
the spleen isolates causing longer incubation periods and
decreased numbers of mice exhibiting signs of prion disease
within their lifespan (Bruce et al., 2001; Bruce, 2003;
Ritchie et al., 2009).
Similar to earlier studies of extraneural tissue transmis-
sion, we ﬁnd that the strain of agent is not altered by the
tissue of origin (Bruce et al., 2001; Ritchie et al., 2009).
In vivo transmission studies have suggested that different
prion strains can be isolated from CNS and lymphoid tissue
in the same host the mechanisms of which are not yet
understood (Beringue et al., 2012). Beringue et al. (2012)
also demonstrated that prions can exist in the periphery for
nearly one-third of a host’s life before CNS detection. In
vCJD a body of evidence including the transmission of
vCJD through blood transfusion (Peden et al., 2004;
Hewitt et al., 2006; Wroe et al., 2006; Gillies et al.,
2009), detection of PrPTSE through PMCA (Bougard
et al., 2016) and in vivo infectivity studies have shown
that prion infectivity can be present without CNS involve-
ment (Bishop et al., 2013). Three retrospective studies in
anonymized UK appendix samples have revealed the pres-
ence of abnormal PrP in all three codon 129 genotypes
(Ironside et al., 2000; Gill et al., 2013; Public Health
England, 2016). This has given a prevalence estimate of 1
in 2000 individuals in the UK with abnormal PrP in their
appendix that could be considered asymptomatic vCJD. It
is currently not known exactly what the abnormal PrP pre-
sent in these appendix samples represents. Possibilities in-
clude infection with vCJD, infection with another prion
disease or artefact unrelated to prion disease. The results
from this study of an asymptomatic individual may be im-
portant in deciphering the results from these retrospective
appendix studies.
We have demonstrated that vCJD strain properties have
not been impacted by host genotype, human-to-human
transmission through blood transfusion, tissue of origin
or point of infectivity in the disease course. However,
with the identiﬁcation of a primary case of clinical vCJD
in a 129 heterozygous individual and abnormal PrP in
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appendixes of all codon 129 genotypes it is clear that con-
tinued human surveillance is required to identify new cases
of vCJD and recognize any differences in disease phenotype
that could be indicative of changes to the prion strain.
Strain characterization studies of the clinical case of pri-
mary vCJD in a codon 129 heterozygous individual are
currently being undertaken. Any changes in prion strain
could lead to changes in infectious properties, which is an
immediate concern for public health and it is essential that
we do not become complacent in our approach to these
fatal diseases.
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